Acyclovir or similar agents with activity against Epstein-Barr virus (EBV) theoretically may prevent non-Hodgkin's lymphoma (NHL) in AIDS. A case-control study of 29 patients with AIDS-related NHL and 58 matched control subjects assessed the frequency with which daily acyclovir (у800 mg/d) or similar agents were used for у1 year. In a historical cohort of 304 patients with AIDS for у2 years, the prevalence of NHL was assessed among 3 groups of patients: those who received long-term treatment with high-dose acyclovir (or similar agents) or low-dose or intermittent acyclovir; those treated with ganciclovir/foscarnet for !1 year; and those who had not previously been treated with acyclovir, ganciclovir, or foscarnet. In the case-control study, 22 patients (72.4%) with NHL never received acyclovir or similar drugs versus 19 control subjects (32.8%; ); 2 patients (6.9%) with NHL received acyclovir P = .002 (у800 mg/d) for у1 year versus 27 (46.6%) of control subjects ( ). In the cohort study, P = .0001 6 (6.8%) of 88 patients who received acyclovir (у800 mg/d) for у1 year developed NHL versus 15 (15.5%) of 97 patients who received intermittent or lower-dose acyclovir and 30 (25.2%) of 119 patients who never received these agents ( ). Long-term administration (11 year) P = .002 of high-dose acyclovir or similar agents with anti-EBV activity may prevent NHL in patients with AIDS. A prospective, randomized study is warranted to confirm these results.
quences have been demonstrated within these tumor cells. These lymphoproliferative disorders have been successfully treated in by reducing immunosuppression and initiating administration of acyclovir [9] [10] [11] in their early stages. Acyclovir causes remission of polymorphic B cell hyperplasia during the early phase of polyclonal growth of lymphoma but is ineffective once the tumor evolves into a monoclonal lymphoma [7] .
See editorial response by Rabkin on pages 762-3.
The uncontrolled polyclonal B cell proliferation is dependent on continued EBV replication and subsequent transformation of additional B cells. Acyclovir interrupts EBV replication and thus inhibits continued B cell proliferation. Similarly, ganciclovir and foscarnet are powerful inhibitors of herpesviruses, including herpes simplex virus, cytomegalovirus, varicella-zoster virus, and EBV [12] . Moreover, there are in vitro data indicating that both ganciclovir [13] and foscarnet [14] may be more active than acyclovir against EBV. These studies were designed to determine whether long-term daily usage of acyclovir (and ganciclovir or foscarnet) is associated with protection against NHL.
Patients and Methods
Case-control study. A retrospective review was performed of charts from the medical records of St. Michael's Hospital and the offices of 3 primary-care HIV-specialist physicians in Toronto.
The study population comprised patients with HIV infection Cohort study. A retrospective review was performed of charts from the same sources as in the case-control study. The study population comprised patients with AIDS (of у2 years' duration) diagnosed by the 1993 criteria of the Centers for Disease Control and Prevention (CDC, Atlanta) [15] .
Measurements. Demographic data collected were as follows: risk factor for HIV; duration of AIDS or of a CD4 cell count !200/ L; duration and type of antiretroviral treatment; duration and dosages of acyclovir, ganciclovir, foscarnet, and famciclovir treatment; number and types of major opportunistic infections; presence or absence of NHL, as well as type of NHL, date of diagnosis, treatment received, and outcome; and condition at the time of review (alive or dead).
Statistical analysis. For continuous data the Student's t test was used, and for categorical data, contingency table analysis (Fisher's exact test or x 2 test) was used.
Results
Case-control study. There were 29 case patients and 58 control subjects, for which the effectiveness of matching is shown in table 1. The complicating diseases in the 2 groups are summarized in table 2. Kaposi's sarcoma occurred much more frequently among the control subjects than among the case patients (31% vs. 13.8%, respectively; by Fisher's exact P = .66 test), but none of these patients received specific chemotherapy. Since long-term ganciclovir or foscarnet treatment (for у1 year) was used by only 1 NHL case patient and 1 control subject, the analysis was restricted to acyclovir usage. Table 3 shows a comparison of the usage of acyclovir at low or intermittent dosing and at high daily dosing (у800 mg/d) for у1 year in the 2 groups. As can be seen, among control subjects there was significantly greater use of high doses of acyclovir than among case patients ( ). P = .0001 Cohort study. There were 304 HIV-infected patients fulfilling the criteria for the cohort study. They were divided into 3 groups: group I received daily acyclovir (у800 mg/d) or iv ganciclovir or foscarnet for у1 year; group II received intermittent or lower-dose acyclovir or ganciclovir/foscarnet for !1 year; group III received no acyclovir, ganciclovir, or foscarnet. The demographic features of the patients are shown in table 4, and there were some significant differences between the groups. Group I had a higher percentage of homosexuals and fewer blood-related risk factors than did group III; patients in group I also had longer durations of CD4 cell counts !200/L and of exposure to antiretrovirals, as well as a higher rate of previous AIDS-related events.
The prevalence of NHL in the 3 groups are shown in figure 1. Patients in group I had the lowest rate of NHL ( ; P = .0020 x 2 analysis). Thus, the relative risk of NHL for patients receiving high-dose acyclovir (or ganciclovir or foscarnet) for у1 year was 0.27 in comparison with the rate for patients who never received those agents (group III). Most of the patients in group I or II received acyclovir, and only a few patients received ganciclovir or foscarnet (9 in group I and 17 in group II). None of the patients received famcyclovir or valciclovir after diagnosis of NHL had already been confirmed, except 1 patient with herpes zoster.
With respect to the clinical subtypes of lymphoma, the distribution of CNS NHL in the various groups was as follows: group I, 3 (3.4%); group II, 9 (9.3%); and group III, 6 (5%) (
). There was only 1 body-cavity NHL (in group III); P = .24 the other cases of NHL involved the viscera or lymph nodes.
Discussion
The estimated risk of lymphoma developing in a patient with symptomatic HIV infection has ranged from 1% to 2% per year [16, 17] and as high as 10% and 29% 3 years after introduction of antiretroviral therapy with didanosine and zidovudine, respectively [18] . The incidence of AIDS-related lymphoma has been substantially underestimated because of several factors. First, the CDC collects data on initial AIDS-defining events only, although most lymphomas appear most frequently in the end stages of AIDS, when immunity is markedly impaired. Recent analysis by Pluda et al. [18] showed that the greatest risk of NHL was for patients with !50 CD4 cells/L. Second, most primary lymphomas of the CNS are diagnosed only at the time of autopsy. Various estimates place the overall incidence of NHL in AIDS between 4% and 10% [19, 20] . The risk for NHL in the United States is calculated to be 60 times greater for persons who have AIDS than for the general population [21] .
In our initial case-control study there was a significantly lower long-term usage of high-dose acyclovir for у1 year by NHL case patients than by control subjects (6.9% vs. 46.6%). Moreover, 72.4% of patients with NHL versus 32.8% of control subjects, never received acyclovir before development of lymphoma ( ). Although there was a higher prevalence of P = .0002 Kaposi's sarcoma among control subjects than among case patients, this probably did not bias our findings. In fact, the converse might be expected, because infection with human herpesvirus type 8 (which has been associated with Kaposi's sarcoma) has also been associated with body-cavity lymphoma [21] .
In the cohort study, patients receiving high-dose acyclovir or ganciclovir/foscarnet for у1 year had NHL at the lowest rate (6.8%); patients receiving low, intermittent doses of acyclovir or ganciclovir/foscarnet for р1 year had a intermediate rate of NHL (15.5%), and those who received none of these agents had the highest rate (25.2%). These data show an association between protection of AIDS patients from lymphoma and the use of high-dose acyclovir (or ganciclovir/foscarnet) for 11 year. The prevalence rate of NHL in the high-dose acyclovir group was one-third the rate among those not exposed to the anti-EBV agents.
There was no significant decrease in CNS NHL with acyclovir usage; this may be because of the relative small sample sizes, but may be because oral acyclovir achieved inadequate concentrations in the brain. Although the demographic features of the 3 groups in the cohort study were not fully matched, it is not likely that factors such as female sex or blood products contributed to the higher rate of NHL in group III, since none of these patients had lymphoma. It is very likely that group I patients had a higher prevalence of herpes simplex, herpes zoster, and cytomegalovirus infections. This might perhaps explain the reduced prevalence of NHL, but there is no evidence or plausible biological explanation to support this theory.
Moreover, the usage of prolonged daily high doses of acyclovir was in vogue in the community at one time, even for patients without previous herpes simplex or herpes zoster infection. This trend was based on study findings showing that high-dose acyclovir in combination with zidovudine (in comparison with zidovudine alone) prolonged life (for the short term) for patients with AIDS [22] . It should be noted that group I patients may have even a greater risk of NHL than group III patients, in view of the longer duration of low CD4 counts (!200/L), greater duration of antiretroviral therapy, and greater number of prior AIDS-related events. However, with these biases, this group in fact had a lower prevalence of NHL than the other 2 groups, which indicated a possible protective benefit of the anti-EBV agents.
Alternatively, it could be argued that patients in group III had a higher prevalence of NHL because they were less immunosuppressed. However, in studies of both animals and humans, the converse has been found: the greater and more prolonged the immunosuppression, the greater the risk of NHL.
The simplest model to explain the role of EBV in NHL that occurs in HIV-infected patients is the loss of cytotoxic CD8 cells and natural killer cell immunosurveillance that allow the outgrowth of latently EBV-infected B cells. The weakened immunosurveillance permits viral replication and accelerates B lymphocyte transformation. EBV-associated tumors express both latent and early lytic-cycle genes and undergo lytic viral DNA replication [23] . The lytic-phase EBV DNA replication is sensitive to antiviral drugs such as acyclovir, whereas the latent phase is not [24] .
The main limitations of our studies include the retrospective design and relatively small sample sizes. In addition, because of the retrospective nature of the study and the fact that some cases of NHL were diagnosed at other institutions, we do not have data on the EBV status of the lymphomas in patients receiving or not receiving acyclovir and thus cannot make correlations with our findings.
In conclusion, our studies suggest that long-term use of highdose acyclovir or similar antiviral agents may offer some protection against development of NHL in patients with AIDS. However, for confirmation of these findings, a prospective, randomized, controlled study is warranted.
